ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 732

Impact of Disease Course on Atherosclerotic Vascular Events, Osteoporosis and Osteonecrosis in Systemic Lupus Erythematosus

Konstantinos Tselios, Dafna D Gladman, Zahi Touma, Jiandong Su, Nicole Anderson and Murray Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: Co-morbidities and systemic lupus erythematosus (SLE)

Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We have shown that disease course over time in systemic lupus erythematosus (SLE) follows three distinct patterns (prolonged remission, relapsing remitting and persistently active). The impact of these patterns on the development of specific co-morbidities, such as atherosclerotic vascular events (AVEs), osteoporosis and osteonecrosis is not known. The aim of the present study was to assess the incidence of such co-morbidities in lupus patients in the long term.

Methods: The inception patients of our long-term longitudinal cohort (enrolled within 18 months of diagnosis), with at least 10 years of follow-up and no time interval >18 months between consecutive visits, were investigated. Prolonged remission (PR) was defined as a clinical SLEDAI-2K=0 [serology (anti-dsDNA antibodies and C3/C4 levels) excluded], achieved within five years since enrolment and maintained for ≥10 years after that. Relapsing-remitting (RR) pattern was defined based on ≥2 remission periods (one remission period equals two consecutive visits with a clinical SLEDAI-2K=0), while patients with no remission were categorized as persistently active (PA). Incidence rates for AVEs (angina, myocardial infarction, re-vascularization procedure, transient ischemic attack, stroke, peripheral vascular disease), osteoporosis (according to the WHO definition) and osteonecrosis (confirmed radiologically) were calculated at 10 years and at the end of follow-up (median 17.5 years).

Results: Of 267 patients who fulfilled the inclusion criteria, 27 (10.1%) achieved PR, 180 (67.4%) were RR and 25 (9.4%) PA. At enrollment, there were no significant differences in demographic, clinical, immunological and therapeutic characteristics among the groups. At 10 years, PA patients had received significantly more glucocorticosteroids [39.4±24.3g vs. 16.6±10.7g and 27.3±18.4g for the PR and RR groups, p<0.001]. The incidence rates of AVEs, osteoporosis and osteonecrosis at 10 years and for the entire duration of follow up are given in Table 1.

Table 1. Incidence rates (/100 patient-years) of AVEs, osteoporosis and osteonecrosis in all patients

 

PR (n=27)

RR (n=180)

PA (n=25)

p

Age at enrolment (mean±SD)

39.2 ± 14.1

35.2 ± 13.4

37 ± 13.9

0.142

At 10 years

AVEs (incidence, n, %)

0

2.7

4.3

0.002

Osteoporosis (incidence, n, %)

0.4

7.6

8.5

<0.001

Osteonecrosis (incidence, n, %)

8.5

10.3

12.4

0.142

At the end of follow-up

AVEs

0.75

6.4

8

<0.001

Osteoporosis

6.6

14.1

12.3

0.004

Osteonecrosis

10.7

16.5

18

0.001

P value from ANOVA (Analysis of Variance) for age and Cochran-Armitage trend test for all rates (between PR and the other groups). No differences were observed between the RR and PA groups.

Conclusion: Disease course had a significant impact on the rates of atherosclerotic vascular events, osteoporosis and osteonecrosis over time. Patients who had achieved prolonged remission developed significantly fewer such co-morbidities whereas the differences between the RR and PA patients were not statistically significant. 

 


Disclosure: K. Tselios, None; D. D. Gladman, None; Z. Touma, None; J. Su, None; N. Anderson, None; M. Urowitz, None.

To cite this abstract in AMA style:

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz M. Impact of Disease Course on Atherosclerotic Vascular Events, Osteoporosis and Osteonecrosis in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/impact-of-disease-course-on-atherosclerotic-vascular-events-osteoporosis-and-osteonecrosis-in-systemic-lupus-erythematosus/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-disease-course-on-atherosclerotic-vascular-events-osteoporosis-and-osteonecrosis-in-systemic-lupus-erythematosus/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology